Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $75.00 Average PT from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $75.00.

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Barclays started coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective on the stock. JonesTrading upped their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Mizuho raised their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Finally, Stifel Nicolaus lifted their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, August 6th.

Insider Activity at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the transaction, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at approximately $2,345,308.88. This represents a 13.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares of the company’s stock, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 180,831 shares of company stock worth $10,735,269 over the last 90 days. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. KBC Group NV acquired a new stake in Enliven Therapeutics in the first quarter valued at $38,000. State of Wyoming acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth $96,000. FNY Investment Advisers LLC purchased a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $126,000. WINTON GROUP Ltd acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at about $228,000. Finally, Squarepoint Ops LLC acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at about $259,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $53.36 on Wednesday. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The firm has a 50-day simple moving average of $56.53 and a 200-day simple moving average of $45.75. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of -31.95 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts forecast that Enliven Therapeutics will post -1.69 EPS for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.